Clinical Trials on Acute Agitation, Behavioural Emergency in Hungary

Total 3 results

Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Belgium, Canada, Chile, Colombia, Croatia, Hungary, Mexico, Netherlands, Slovakia, Slovenia, Spain, Ireland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Bulgaria, France, Poland
Otsuka Pharmaceutical Development & Commercialization...

Completed

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

Spain, United States, Italy, United Kingdom, Hungary, France, Poland, Australia, Bulgaria, Czechia, South Africa

3

Subscribe